# A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

> **NCT04498247** · PHASE1,PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 263 (actual)

## Conditions studied

- Coronavirus Disease (COVID-19)

## Interventions

- **BIOLOGICAL:** V591
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04498247
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-27
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-03-05
- **Target enrollment:** 263 (ACTUAL)
- **Why stopped:** The study was terminated based on an interim assessment of immunogenicity
- **Last updated:** 2021-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498247, "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04498247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*